A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks.

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Participants were randomly allocated to receive subcutaneous semaglutide 1.0 mg once per week for 52 weeks or placebo (396 patients in each group). The researchers found that the estimated median ...

Eight canines were randomized into two equal groups who received either 0.5 mg of semaglutide delivered via the RP or ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of ...